On April 4, 2016 CRT reported that it has signed an agreement with CiMass, under which CiMass will test a proprietary monoclonal antibody in combination with natural killer cells for the treatment of cancer (Press release, Cancer Research Technology, APR 4, 2016, View Source [SID1234523501]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CiMaas is developing cellular immunotherapy for various cancer patients, including natural killer cells for adoptive transfer to patients with breast cancer and multiple myeloma. Natural killer cells are able to efficiently kill cancer cells, but this killing can still be enhanced by addition of monoclonal antibodies. The current agreement allows CiMaas to further develop a monoclonal antibody directed against an undisclosed target to enhance the immune response mediated by natural killer cells to tumour tissue.

CiMaas will use additional technology to improve the antibody and test its efficacy in proof of concept experiments. Under the agreement CiMaas receives one year exclusivity to explore the antibody’s functionality in natural killer cell-related therapies and CRT receives a signature fee in return.